Abstract 4842
Background
The incidence of pancreatic cancer (PAC) has continued to rise in recent years. PAC can be divided into head of PAC (HPAC) and body/tail of PAC (BTPAC) by the anatomical location. The patients (pts) with BTPAC are usually diagnosed at relatively advanced stage and had worse survival than those with HPAC. The comparative molecular signatures between different locations in Chinese PAC pts remain unclear.
Methods
154 tumor specimens (HPAC, N = 85; BTPAC, N = 69) and matched normal blood samples of Chinese PAC pts were detected and analyzed in a CAP&CLIA certified laboratory (OrigiMed company) with Yuansu panel including 450 genes. Total 100 males (65%) and 54 females (35%) with a mean age of 61 years old (yrs) were enrolled. We measured the somatic variations and calculated tumor mutational burden (TMB) after filtering known driver mutations (muts). Meanwhile, germline muts were analyzed among the tumor susceptibility genes. Fisher tests were used for comparative analyses.
Results
The median age in HPAC and BTPAC was 60 yrs and 62 yrs. Pts with stage 3&4 accounted for 40% and 60% in HPAC and BTPAC (P<0.05). Genomic alterations of KRAS and SMAD4 were significantly more prevalent in BTPAC (KRAS in BTPAC vs. HPAC= 97% vs. 82%, P=0.004; SMAD4 in BTPAC vs. HPAC= 42% vs. 21%, P=0.008). 2 NTRK3 fusions (3%) were found in BTPAC but 0 in HPAC. Additionally, muts frequency in Wnt pathway was 57% in BTPAC, whereas 37% in HPAC (P=0.02). No significant difference was found in TP53 (83% vs. 81%), CDKN2A (32% vs. 27%) and germline muts frequency (12% vs. 14%) between BTPAC and HPAC, nor in the mean TMB value (3.22 muts/Mb vs. 3.59 muts/Mb). For HPAC, there were more muts in HR pathway genes (24% vs. 19%), although the difference was not statistical significance. 2 BRCA2 germline muts were found in HPAC but neither BRCA1 nor BRCA2 was found in BTPAC.
Conclusions
Genomic pattern did not show apparent difference between the anatomic locations of PAC. However, we found more driver muts in KRAS and SMAD4 and more Wnt pathway muts related to proliferation and metastasis in BTPAC. Further research should be done to better understand the cancer biology among the locations and identify more therapy targets for precision medicine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3059 - Intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial
Presenter: Rongxin Zhang
Session: Poster Display session 2
Resources:
Abstract
3082 - Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): a pooled analisys of TRIBE and TRIBE-2 studies by GONO
Presenter: Emanuela Dell'Aquila
Session: Poster Display session 2
Resources:
Abstract
3618 - Drug holidays and overall survival in patients treated for metastatic colorectal cancer
Presenter: Silvio Ken Garattini
Session: Poster Display session 2
Resources:
Abstract
6111 - Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)
Presenter: Michael Geissler
Session: Poster Display session 2
Resources:
Abstract
1042 - A biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastastic colorectal cancer : results of phase I of the PERMAD trial
Presenter: Thomas Seufferlein
Session: Poster Display session 2
Resources:
Abstract
3291 - Microsatellite Instability (MSI) status and prognosis in colorectal cancer: meta-analysis
Presenter: James Toh
Session: Poster Display session 2
Resources:
Abstract
2046 - Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer.
Presenter: Miriam Koopman
Session: Poster Display session 2
Resources:
Abstract
2589 - Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer
Presenter: Stefan Kasper
Session: Poster Display session 2
Resources:
Abstract
4944 - POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers
Presenter: Maria Elena Elez Fernandez
Session: Poster Display session 2
Resources:
Abstract
2042 - The accuracy of the clinical PCI score in patients with peritoneal carcinomatosis of colorectal cancer
Presenter: Nadine De Boer
Session: Poster Display session 2
Resources:
Abstract